首页|期刊简介|投稿指南|分类索引|刊文选读|订阅指南|资料|样刊邮寄查询|常见问题解答|联系我们
崔长升,齐滨,刘莉,等. 基于网络药理学探讨润通莱蜜丸对慢传输型便秘小鼠的作用机制[J]. 科学技术与工程, 2020, 20(16): 6385-6390.
cui chang sheng,et al.Study on the Mechanism of Runtonglaimi Pill in Slow Transit Constipation Mice Based on Network Pharmacology[J].Science Technology and Engineering,2020,20(16):6385-6390.
基于网络药理学探讨润通莱蜜丸对慢传输型便秘小鼠的作用机制
Study on the Mechanism of Runtonglaimi Pill in Slow Transit Constipation Mice Based on Network Pharmacology
投稿时间:2019-09-09  修订日期:2020-06-14
DOI:
中文关键词:  网络药理学 润通莱蜜丸 STC PTGS
英文关键词:network pharmacology runtonglaimi pill STC PTGS
基金项目:吉林省教育厅“十三五”科学技术项目(JJKH20181246KJ)
           
作者单位
崔长升 长春中医药大学
齐滨 长春中医药大学
刘莉 长春中医药大学
张昊旻 长春中医药大学
摘要点击次数: 77
全文下载次数: 40
中文摘要:
      摘 要 为考察润通莱蜜丸对慢传输型便秘(STC)小鼠的治疗作用及机制,通过借助中药系统药理学分析平台(TCMSP)检索枳实、白术、莱菔子的化学成分和作用靶点,以“slow transit constipaton”为关键词在GenCards数据库中检索与STC相关的基因,构建化合物-靶点网络,预测润通莱蜜丸调控的靶点。将50只小鼠分为空白对照组、模型对照组、阳性对照组、低剂量组和高剂量组,以盐酸洛哌丁胺胶囊(1.5mg/kg)经口灌胃建立STC便秘模型,造模成功后,阳性对照组给予枸橼酸莫沙必利片(2.5mg/kg)经口灌胃;低剂量组、高剂量组给予润通莱蜜丸25mg/10g、50mg/10g经口灌胃治疗,每天2次,共7天。检测各组小鼠小肠炭末推进率、结肠内大便粒数、观察结肠病理结构、小鼠结肠组织中cox-1、cox-2的表达量。结果表明:网络药理学共筛选出35个活性化合物,有21个化合物和42个靶点参与了网络构建,其中PTGS1(cox-1)与活性化合物连接度最高,可能为润通莱蜜丸调控的重要靶点。动物实验表明,润通莱蜜丸可提高慢传输型便秘小鼠小肠炭末推进率、减少结肠中大便粒数,恢复结肠的结构、降低慢传输型便秘小鼠结肠中cox-1、cox-2含量(P<0.01)。可见,润通莱蜜丸可以缓解慢传输型便秘,其机理可能是通过调节cox-1、cox-2实现的。
英文摘要:
      [Abstact] In order to investigate the therapeutic effect of Runtonglaimi pill on slow transit constipation (STC) mice and its possible therapeutic mechanism. The chemical constituents and target sites of citrus aurantium, atractylodes, and scorpion scorpion were searched by the Chinese Medicine System Pharmacology Analysis Platform (TCMSP). The genes related to STC were searched for by “slow transit constipaton” using the GenCards database. Targets and disease targets intersect genes to construct a compound-target network. 50 mice were divided into blank control group, model control group, positive control group, low-dose group and high-dose group. The STC constipation model was established by oral gavage with loperamide hydrochloride capsule (1.5mg/kg). After successful model, the positive control group was given mosapride citrate tablets (2.5mg/kg) by oral gavage; the low-dose group and high-dose group were given Runtonglaimi pill dilutions 0.05ml/ 10g, 0.1ml/ 10g oral gavage treatment, 2 times per day, a total of 7 days. The propensity of charcoal in the mice, the number of stool cells in the colon, the pathological structure of the colon, and the expression of cox-1 and cox-2 in the colon of the mice were measured. The result show that a total of 35 active compounds were screened by network pharmacology. Twenty-one compounds and 42 targets were involved in network construction. Among them, PTGS1 (cox-1) had the highest degree of connectivity with active compounds. Animal experiments show that Runtonglaimi pill can improve the intestinal propulsion rate of slow transit constipation mice, reduce the number of stool cells in the colon, restore the structure of the colon, and reduce the cox-1 and cox- in the colon of slow transit constipation mice(P<0.01). It is concluded that Runtonglaimi pill can alleviate slow transit constipation, and can relieve slow transit constipation by adjusting cox-1 and cox-2.
查看全文  查看/发表评论  下载PDF阅读器
关闭
你是第31355067位访问者
版权所有:科学技术与工程编辑部
主管:中国科学技术协会    主办:中国技术经济学会
Tel:(010)62118920 E-mail:stae@vip.163.com
京ICP备05035734号-4
技术支持:本系统由北京勤云科技发展有限公司设计

京公网安备 11010802029091号